viewPreveCeutical Medical Inc.

PreveCeutical Medical successfully infuses CBD with its Sol-gel pain-relief technology

The company is developing the sustained-release Sol-gel program for nose-to-brain delivery of medical compounds, including cannabinoids like CBD

CBD Sol-gel formulations are expected to allow for prolonged delivery of cannabinoids to a patients' central nervous system

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS: PRVCF) announced Tuesday that it has successfully infused CBD with its flagship Sol-gel technology.

The Canadian health-sciences company is developing the sustained-release Sol-gel program for delivery of medical compounds, including cannabinoids like CBD, to provide relief from pain, inflammation, seizures and neurological disorders.

With the use of an applicator, Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.

PreveCeutical's announcement marks the end of the second testing phase of Sol-gel in which the company successfully developed wholly-water based, CBD-infused formulations that incorporated both acid and neutral cannabis-extract forms.

READ: PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing

The third and final stage of the Sol-gel program is currently underway. The third phase is expected to assess and profile cannabinoid release from the extract infused Sol-gels, as well as how CBD is deposited into nasal mucosal tissue (ex vivo). The company will also conduct a toxicity evaluation.

"It will be exciting to see how these ongoing ex-vivo studies conducted using human explanted tissues may help us get an early read out on our proprietary drug delivery applicator device for the targeted central nervous system delivery of cannabinoids,’ said Mak Jawadekar, PreveCeutical's president and chief science officer.

CBD Sol-gel formulations

The CBD Sol-gel formulations are expected to allow for the direct and prolonged delivery of cannabinoids to a patients' central nervous system.

Future studies, outside of the current Sol-gel program, may involve pre-clinical/clinical evaluation of the CBD Sol-gel formulations as the company's medicinal cannabis division hopes to offer a broad product range of formulations that can be tailored to specific medical conditions.

PreveCeutical, based in Vancouver, is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

The company’s stock was flat at C$.045 in Canada but fell 2.5% to $0.035 on the OTC Markets.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: PreveCeutical Medical Inc.

Price: 0.04 CAD

Market: CSE
Market Cap: $19.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 07/23/2020

2 min read